
FDA approves phase 1/2 clinical trial with ABX196 in patients with liver cancer ABX196 to be tested in combination with checkpoint inhibitor nivolumab to treat hepatocellular carcinoma
May 14, 2019
LA JOLLA, CA The U.S. Food and Drug Administration has approved an investigational new drug (IND) application for a phase 1/2 clinical trial of ABX196, a liver cancer therapy developed in the laboratory of Scripps Research Professor Luc Teyton, MD, PhD, and licensed to French pharmaceutical company Abivax.
The FDA approval allows Abivax testing of ABX196 in patients with hepatocellular carcinoma (HCC), the most common form of liver cancer. ABX196 showed potent efficacy against HCC in preclinical testing.
The translation of basic research discoveries to the clinic is the greatest achievement we can hope for as clinician scientists. says Teyton, who is also a member of Abivax's Scientific Advisory Board. The use of ABX196 in the context of immunotherapy has been shown to be beneficial in multiple animal models of cancer, but the results with hepatocellular carcinoma are spectacular. We are looking forward to impacting the disease in patients, especially given the limitations of current therapies.
The open IND allows Abivax to test ABX196 in combination with nivolumab (Opdivo, Bristol-Myers Squibb), a checkpoint inhibitor, in a first phase 1/2 clinical trial to treat patients with HCC. The initial dose-escalation phase of the study will be conducted at the Scripps MD Anderson Cancer Center in San Diego, California, USA; additional leading cancer centers in the U.S. will be involved in the subsequent expansion phase of the study. The first patient is expected to be enrolled this summer.
We are thrilled to have been given the green light by FDA for our U.S. study. says Hartmut J. Ehrlich, MD, chief executive officer of Abivax. This open IND allows Abivax, in collaboration with leading key opinion leaders at internationally renowned U.S. cancer centers of excellence, to explore the clinical potential of our iNKT agonist ABX196 to broaden and potentiate the activity of the checkpoint inhibitor nivolumab. Based on its unique mechanism of action and exciting preclinical data in several cancer models, we believe ABX196 is a promising immunotherapeutic product candidate for patients with liver cancer that may also have potential in other cancers.
ABX196 is a synthetic glycolipid agonist of invariant natural killer T cells (iNKT) in a liposomal formulation. A phase 1 clinical trial conducted by Abivax in healthy volunteers has been completed and demonstrated safety and tolerability as well as a potent activation of iNKT cells. ABX196, both alone and in combination with a checkpoint inhibitor, showed a statistically highly significant therapeutic effect in reducing tumor growth as measured by MRI and increasing survival in mice with HCC. Abivax holds exclusive rights to ABX196 from Scripps Research, the University of Chicago, and Brigham Young University.
Despite the recent introduction of checkpoint inhibitors, hepatocellular carcinoma continues to be a substantial therapeutic challenge, as only about 20 percent of the treated patients show a response to these new drugs says Darren Sigal, MD, program director of GI Oncology at Scripps Clinic and Scripps MD Anderson Cancer Center in San Diego, and principal investigator of the study. While checkpoint inhibitors block a do not attack me' signal on cancer cells, ABX196 activates iNKT cells, a subpopulation of lymphocytes that is critical for mounting an effective immune response. The synergy between these two molecules carries substantial promise for improved outcomes for patients with this deadly cancer.
Checkpoint inhibitors like nivolumab are a leading class of therapeutic monoclonal antibodies that block certain endogenous proteins (PD-1/PDL-1) made by immune cells, such as T cells, as well as some cancer cells. These proteins effectively hijack the immune system, causing it to keep immune responses in check and preventing T cells from killing cancer cells. When these proteins are blocked, the brakes on the immune system are released and T cells are able to kill cancer cells much more efficiently. In some cancers, treatment with checkpoint inhibitors has been highly efficacious. However, due to the tumor micro-environment in other cancers, such as HCC, checkpoint inhibitors can have difficulties exerting their effects. ABX196 is intended as a drug that will potentiate the efficacy of checkpoint inhibitors by activating iNKT cells to kill tumor cells.
HCC is the most common form (75 to 90 percent) of primary liver cancer in adults. It typically occurs in the setting of chronic liver inflammation and/or cirrhosis and is closely linked to chronic viral infection such as hepatitis B or C, exposure to toxins such as alcohol, and to certain diseases such as non-alcoholic steatohepatitis (NASH).
The incidence of and deaths related to HCC are increasing in the United States and globally due to hepatitis B and C virus infections, as well as NASH. Prevalence data from 2018 show a total of 79,000 cases of HCC in the U.S. and G5 Europe (Germany, France, Italy, Spain and the UK), with 67,000 new cases, and a total of 260,000 cases in China with 338,000 new cases. Globally, there were 841,000 new cases of liver cancer (ranking it sixth of all reported cancers) and 782,000 fatalities (ranking it fourth) in 2018.
Currently, the American Cancer Society reports five-year survival rates in the U.S. of 31 percent for localized HCC, 11 percent for regional, and 2 percent for distant or metastatic, indicating a clear unmet medical need for improved therapies for HCC.
Cancer Immunology & Microbiology Teyton, Luc
Most recent headlines
05/01/2027
Worlds first 802.15.4ab-UWB chip verified by Calterah and Rohde & Schwarz to be ...
17/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
17/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
17/11/2026
LA JOLLA, CA-Two Scripps Research faculty, Assistant Professor Christian Diercks...
16/11/2026
The ESPN Edge Innovation Conference once again gave key ESPN technology partners as a chance to take to the stage and discuss the future of sports fan experienc...
16/11/2026
As rights holders rethink who tells their stories and where, IMG is preparing th...
16/11/2026
From the sidelines, sonic savants advocate for greater emphasis on sound as sports and entertainment increasingly merge
SVG Live!, a one-day event on Nov. 10 i...
16/11/2026
Deal combines Yamaha's audio technology with Disguise's visual-productio...
16/11/2026
Creative effects designed to encourage experimentation
Berry Effects is the brainchild of Abe and Ralph, a pair of multi-instrumentalists and audio engineer...
16/11/2026
Physics-based synth gets first major update
Anukari have just released a new version of their innovative physics-based software synth, marking the instrumen...
16/11/2026
Both versions kitted out with new tools & improvements
Hit'n'Mix have just launched the latest major version of their innovative DAW software, with ...
16/11/2026
Dynamic bands, unmasking features & new stereo tools
Launched in 2021, Eventide's SplitEQ plug-in introduced an interesting new approach to EQ, with the...
16/11/2026
Rohde & Schwarz Japan demonstrates multi-vendor ASA-ML communication with high p...
16/11/2026
November 16, 2026
Hitachi system enables proton beams to be delivered from 360 degrees around the patient, expanding treatment capacity and supporting more pre...
16/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
16/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
16/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
16/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
16/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
16/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
16/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
16/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
16/11/2026
Hiltron Communications has received a repeat order from one of Europes longest established communications satellite operators. Central to this project is a Hilt...
16/11/2026
Fabric Insights and Fonn Group today announce a partnership to connect editorial planning and media operations across their complementary product portfolios.
...
16/11/2026
Density 1.0 brings a complete color grading workflow to Final Cut Pro
Brie Clayton November 16, 2026
0 Comments
Filmmaker Pascal Basel's plugin pr...
16/11/2026
Berklee Students to Perform at Boston's CITGO Sign Relighting Kuper Walker, Ollie Mann, and dreamcorp. will perform at the free public celebration in Kenm...
16/11/2026
The Hollywood Reporter Names Berklee Among World's Best Music Schools The annual list spotlights Berklee's screen scoring programs and new master'...
16/11/2026
Five years ago, Lightware launched the original Taurus UCX with a clear vision: USB-C would become the central connection in meeting rooms. The goal was simple:...
16/11/2026
Sonniss: bundles over 80% below their libraries' prices, plus up to 60% off ...
16/11/2026
Singaporean Comedy Luck My Life Shot with Blackmagic URSA Cine 17K 65
Brie Clayton November 16, 2026
0 Comments
Blackmagic PYXIS 12K and DaVinci Resol...
16/11/2026
At SC26, an annual supercomputing conference taking place this week in Chicago, NVIDIA is introducing the DGX Spark HPC Developer Kit for researchers, academics...
16/11/2026
Images available HERE
UKTV has announced Fleet Street (6x60'), a new period crime drama from Miss Scarlet creators Rachael New and Ben Edwards, coming to f...
16/11/2026
November 16th, 2026
TRIBECA FESTIVAL LISBOA UNVEILS 2026 FILM LINEUP AND TALE...
16/11/2026
From Graham Norton to Olivia Attwood and Joe Marler, a new collection of hit vid...
16/11/2026
As countries gather to discuss climate targets at COP 31 this week, one question that is at the heart of debates is how to measure the environmental impact of t...
16/11/2026
Announced today at SC26, NVIDIA Rubin HPC is a new GPU in the NVIDIA Vera Rubin ...
16/11/2026
This week at SC26, NVIDIA is marking two decades of CUDA by honoring the researchers, developers and engineers who helped make GPU computing a foundation for mo...
16/11/2026
With expanded NVIDIA CUDA-X libraries, including cuPhoton, cuPotential and cuSpa, researchers can sift through vast amounts of data to accelerate research, from...
16/11/2026
In its MLPerf benchmarks debut, with results released today, the NVIDIA Vera Rub...
16/11/2026
Quantum processor deployments at supercomputing centers have grown nearly sevenfold over the past five years, with nearly 30 supercomputing centers around the w...
16/11/2026
To train an AI model, thousands of GPUs have to work together, requiring a network that's fast, efficient and resilient.
Lambda is tackling the network pie...
15/11/2026
Mixers, interfaces & DAW controller receive new firmware
Yamaha have just launched a trio of firmware updates that bring some powerful new functionality to ...
15/11/2026
Can VideoProc AI Really Reduce Noise and Enhance Blurry, Old Footage? Real-World...
15/11/2026
Over two days at COEX, more than 2,000 attendees converged for AI Day Seoul, bri...
14/11/2026
Longtime MLB Network employee David Maybrown passed away Thursday at the age of 57. David joined MLB Network in 2009 shortly after its launch, beginning as an i...
14/11/2026
Modular innovators introduce two guitar-based products
ADDAC System's recently introduced Four String Series makes it possible to integrate physical str...
14/11/2026
Marcelo Dai's Live Session Captured with URSA Cine Immersive
Brie Clayton November 14, 2026
0 Comments
Artist takes viewers on an immersive journe...
14/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
14/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
14/11/2026
Newest Lenses, Horizon Anamorphic Seminar & Guided Lens Character Experience Highlight Creative Possibilities
At the 2026 Toru CAMERIMAGE Film Festival, ZEISS...